Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients.

ABSTRACT: Peptide‑based cancer vaccines have failed to provide sufficient clinical benefits in order to be approved in clinical trials since the 1990s. To understand the mechanisms underlying this failure, the present study investigated biomarkers associated with the lower overall survival (OS) among 2,588 patients receiving personalized peptide vaccination (PPV). Survival data were obtained from a database of 2,588 cancer patients including 399 patients with lung, 354 with prostate and 344 with colon cancer. They entered into phase II clinical trials of PPV in which 2 to 4 of 31 warehouse peptides were selected for vaccination on an individual patient basis based on human leukocyte antigen (HLA) class IA‑types and pre‑existing peptide‑specific IgG levels. Higher pre‑vaccination neutrophil, monocyte

SUBMITTER: Suekane S 

PROVIDER: S-EPMC7170040 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature